IRCT20110802007202N15 IRCT 2018-11-08 Tehran University of Medical Sciences Methylphenidate and atomoxetine in attention deficit hyperactivity disorder Comparison of the effectiveness of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in adult patients 2018-08-01 anticipated 36 Complete https://irct.ir/trial/7635 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For designating patients in 2 groups, blocked randomization method is used. The unit of randomization is individual-based and due to the sample size of 36, eighteen of 2-unit blocks are generated. In order to determine the random sequence, “Coin Flip” method is used for assigning the first patient in each block. The first patient is placed in group A if the “head” side is seen as the result of the coin flip and if otherwise, the “tail” is seen, the patient is placed in group B. To generate the random sequence, this process is repeated for next set of blocks until the final patient is designated to the assigned group. To conceal the randomized allocation, the sequentially numbered, opaque sealed envelopes (SNOSE method) is used. 36 opaque numbered envelopes are provided, then each of the sequences is recorded on a card and inserted in an envelope. Finally, the envelopes are placed in a box. At the time of participation of each patient in the trial, the first envelope is opened and the patient 's group is revealed. The random allocation process is done by the hospital pharmacist who does not participate in the study, Blinding description: It is impossible to blind the physician, patient and data coordinator who is the researcher in this study due to the kind of disease and the medicines. This study is single blinded and the analyzer is unaware of the kind of the medicines given to the patients. The data gathered during the study of patients by the researcher is then unknowingly given to the analyzer and statistics expert. 3 Attention deficit hyperactivity disorder in adults. Intervention 1: Intervention group 1: Pharmacotherapy with methylphenidate 10 milligram immediate release tablets ( Ritalin) manufactured by Novartis pharmaceutical industry in Switzerland. The medicine's dosage is determined by psychotherapist but routinely it starts with 5 milligrams three times daily for one week and then it is increased to 10 milligrams three times daily. ( Based on the medicine's effectiveness and adverse effects, the dose can be increased up to 1.2 milligrams per body weight kilograms per day.). Intervention 2: Intervention group 2: Pharmacotherapy with atomoxetine capsules (Stramox) manufactured by Tadbire kalaye jam pharmaceutical industry in Iran. The medicine's dosage is determined by psychotherapist but routinely it starts with 10 milligrams daily for the first week and then the dose is increased to 20 milligrams for the next two weeks and finally to 40 milligrams per day. (Based on the medicine's effectiveness and adverse effects, the dose can be increased up to 1.2 milligrams per body weight kilograms per day.). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information provided.